A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples